Prostate cancer is one of the leading causes of cancer-related death among European men. Discovering the molecules that are implicated in advanced disease is fundamental to therapy.
While promptly diagnosed prostate cancer is curable by surgery or radiotherapy, advanced or metastatic disease is much more difficult to control. Treatment of these patients usually entails androgen withdrawal therapy, which inhibits the activation of androgen receptor (AR) signalling. However, the success of this therapy is limited and cells eventually become resistant.
Further details: Molecular insight into metastatic prostate cancer